Terms: = Lymphoma AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
199 results:
1. Genetic Characterization of Primary Mediastinal B-Cell lymphoma: Pathogenesis and Patient Outcomes.
Noerenberg D; Briest F; Hennch C; Yoshida K; Hablesreiter R; Takeuchi Y; Ueno H; Staiger AM; Ziepert M; Asmar F; Locher BN; Toth E; Weber T; Amini RM; Klapper W; Bouzani M; Poeschel V; Rosenwald A; Held G; Campo E; Ishaque N; Stamatopoulos K; Kanellis G; Anagnostopoulos I; Bullinger L; Goldschmidt N; Zinzani PL; Bödör C; Rosenquist R; Vassilakopoulos TP; Ott G; Ogawa S; Damm F
J Clin Oncol; 2024 Feb; 42(4):452-466. PubMed ID: 38055913
[TBL] [Abstract] [Full Text] [Related]
2. [Relationship between PD-L1 expression and tumor stem cell marker CD44 as a promising basis for the development of new approaches to cancer targeted therapy].
Sotnikova TN; Polushkina TV; Danilova NV
Arkh Patol; 2023; 85(6):70-75. PubMed ID: 38010641
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E; Descourt R; Rousseau-Bussac G; Doubre H; Decroisette C; Demontrond P; Le Garff G; Falchero L; Huchot E; Vieillot S; Corre R; Kazulinski L; Bizieux A; Bigay-Gamé L; Morel H; Molinier O; Chouaïd C; Guisier F
Target Oncol; 2023 Nov; 18(6):905-914. PubMed ID: 37966566
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation and treatment of Primary Spinal Epidural lymphoma Presenting as Acute Myelopathy in a Young Adult: A Case Report.
Cowley RA; Carroll AH; Pasko KBD; Rubenstein E; Tagouri YM; Weiner D
JBJS Case Connect; 2023 Jul; 13(3):. PubMed ID: 37590426
[TBL] [Abstract] [Full Text] [Related]
5. Anaplastic lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults.
Stiefel J; Kushner BH; Roberts SS; Iglesias-Cardenas F; Kramer K; Modak S
JCO Precis Oncol; 2023 Aug; 7():e2300138. PubMed ID: 37561984
[TBL] [Abstract] [Full Text] [Related]
6. Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Manos K; Chong G; Keane C; Lee ST; Smith C; Churilov L; McKendrick J; Renwick W; Blombery P; Burgess M; Nelson NE; Fancourt T; Hawking J; Lin W; Scott AM; Barraclough A; Wight J; Grigg A; Fong CY; Hawkes EA
Leukemia; 2023 May; 37(5):1092-1102. PubMed ID: 36906715
[TBL] [Abstract] [Full Text] [Related]
7. Primary lymphoma of the lumbar vertebrae: a case report and review of the literature.
Safaei S; Azimi P; Yazdanian T; Molanaei S
J Med Case Rep; 2023 Feb; 17(1):45. PubMed ID: 36774514
[TBL] [Abstract] [Full Text] [Related]
8. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
Cholujova D; Beke G; Hunter ZR; Hideshima T; Flores L; Zeleznikova T; Harrachova D; Klucar L; Leiba M; Drgona L; Treon SP; Kastritis E; Dorfman DM; Anderson KC; Jakubikova J
Int J Cancer; 2023 May; 152(9):1947-1963. PubMed ID: 36533670
[TBL] [Abstract] [Full Text] [Related]
9. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
[TBL] [Abstract] [Full Text] [Related]
10. [Study on bone microstructure and pathology of type L2 and L3 osteonecrosis of the femoral head specimens classified by China-Japan Friendship Hospital classification based on "three-columns structure"].
Gao R; Xia X; Liu J; Yuan Z; Huan D; Shen J
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Aug; 36(8):1003-1010. PubMed ID: 35979793
[TBL] [Abstract] [Full Text] [Related]
11. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract] [Full Text] [Related]
12. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract] [Full Text] [Related]
13. Expression of Programmed Cell Death-1 and Programmed Cell Death Ligands in Nodal Peripheral T-Cell lymphoma: Expression Pattern and Potential Prognostic Relevance.
Asawapanumas T; Tangnantachai N; Sukswai N; Assanasen T; Chanswangphuwana C; Lawsut P; Polprasert C; Rojnuckarin P; Bunworasate U; Wudhikarn K
Acta Haematol; 2022; 145(5):542-552. PubMed ID: 35235931
[TBL] [Abstract] [Full Text] [Related]
14. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract] [Full Text] [Related]
15. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF; Burton C; Radford J; Miall F; Townsend W; Santoro A; Zinzani PL; Lewis D; Fowst C; Brar S; Huang B; Thall A; Collins GP
Blood Adv; 2021 Sep; 5(17):3387-3396. PubMed ID: 34477818
[TBL] [Abstract] [Full Text] [Related]
16. Differential Impact of
O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
[TBL] [Abstract] [Full Text] [Related]
17. Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas.
Bednarska K; Nath K; Nicol W; Gandhi MK
Blood Rev; 2021 Nov; 50():100832. PubMed ID: 33896649
[TBL] [Abstract] [Full Text] [Related]
18. Recognition of acute lymphoblastic leukemia and lymphocytes cell subtypes in microscopic images using random forest classifier.
Mirmohammadi P; Ameri M; Shalbaf A
Phys Eng Sci Med; 2021 Jun; 44(2):433-441. PubMed ID: 33751420
[TBL] [Abstract] [Full Text] [Related]
19. Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
Veldman J; Alsada ZND; van den Berg A; Plattel WJ; Diepstra A; Visser L
Br J Haematol; 2021 May; 193(3):506-514. PubMed ID: 33620088
[TBL] [Abstract] [Full Text] [Related]
20. PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.
Abdulla M; Alexsson A; Sundström C; Ladenvall C; Mansouri L; Lindskog C; Berglund M; Cavelier L; Enblad G; Hollander P; Amini RM
Acta Oncol; 2021 Apr; 60(4):531-538. PubMed ID: 33579170
[TBL] [Abstract] [Full Text] [Related]
[Next]
